These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34822948)

  • 41. Implications of ligand-receptor binding kinetics on GLP-1R signalling.
    Zhao P; Truong TT; Merlin J; Sexton PM; Wootten D
    Biochem Pharmacol; 2022 May; 199():114985. PubMed ID: 35300966
    [TBL] [Abstract][Full Text] [Related]  

  • 42. G protein-coupled receptors as regulators of glucose homeostasis and therapeutic targets for diabetes mellitus.
    Tao YX; Liang XF
    Prog Mol Biol Transl Sci; 2014; 121():1-21. PubMed ID: 24373233
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic Functions of G Protein-Coupled Receptors in Hepatocytes-Potential Applications for Diabetes and NAFLD.
    Kimura T; Pydi SP; Pham J; Tanaka N
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and meta-analysis.
    Chadda KR; Cheng TS; Ong KK
    Obes Rev; 2021 Jun; 22(6):e13177. PubMed ID: 33354917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
    Khan MS; Fonarow GC; McGuire DK; Hernandez AF; Vaduganathan M; Rosenstock J; Handelsman Y; Verma S; Anker SD; McMurray JJV; Kosiborod MN; Butler J
    Circulation; 2020 Sep; 142(12):1205-1218. PubMed ID: 32955939
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fatty acid receptors as new therapeutic targets for diabetes.
    Rayasam GV; Tulasi VK; Davis JA; Bansal VS
    Expert Opin Ther Targets; 2007 May; 11(5):661-71. PubMed ID: 17465724
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Deterioration of plasticity and metabolic homeostasis in the brain of the UCD-T2DM rat model of naturally occurring type-2 diabetes.
    Agrawal R; Zhuang Y; Cummings BP; Stanhope KL; Graham JL; Havel PJ; Gomez-Pinilla F
    Biochim Biophys Acta; 2014 Sep; 1842(9):1313-23. PubMed ID: 24840661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.
    Nadeau DA
    Postgrad Med; 2013 May; 125(3):112-26. PubMed ID: 23748512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 50. G protein coupled receptor 18: A potential role for endocannabinoid signaling in metabolic dysfunction.
    Rajaraman G; Simcocks A; Hryciw DH; Hutchinson DS; McAinch AJ
    Mol Nutr Food Res; 2016 Jan; 60(1):92-102. PubMed ID: 26337420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The obestatin receptor (GPR39) is expressed in human adipose tissue and is down-regulated in obesity-associated type 2 diabetes mellitus.
    Catalán V; Gómez-Ambrosi J; Rotellar F; Silva C; Gil MJ; Rodríguez A; Cienfuegos JA; Salvador J; Frühbeck G
    Clin Endocrinol (Oxf); 2007 Apr; 66(4):598-601. PubMed ID: 17371481
    [TBL] [Abstract][Full Text] [Related]  

  • 52. G protein-coupled receptors disrupted in human genetic disease.
    Thompson MD; Percy ME; McIntyre Burnham W; Cole DE
    Methods Mol Biol; 2008; 448():109-37. PubMed ID: 18370233
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Regulation of AMP-activated protein kinase activity by G-protein coupled receptors: potential utility in treatment of diabetes and heart disease.
    Hutchinson DS; Summers RJ; Bengtsson T
    Pharmacol Ther; 2008 Sep; 119(3):291-310. PubMed ID: 18606183
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beta-cell function and mass in type 2 diabetes.
    Larsen MO
    Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intestinal bile acid receptors are key regulators of glucose homeostasis.
    Trabelsi MS; Lestavel S; Staels B; Collet X
    Proc Nutr Soc; 2017 Aug; 76(3):192-202. PubMed ID: 27846919
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [New therapies for type 2 diabetes mellitus].
    Puig-Domingo M; Pellitero S
    Med Clin (Barc); 2015 Jun; 144(12):560-5. PubMed ID: 25194974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacogenetics of the G protein-coupled receptors.
    Thompson MD; Cole DE; Capra V; Siminovitch KA; Rovati GE; Burnham WM; Rana BK
    Methods Mol Biol; 2014; 1175():189-242. PubMed ID: 25150871
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.
    Wang XC; Gusdon AM; Liu H; Qu S
    World J Gastroenterol; 2014 Oct; 20(40):14821-30. PubMed ID: 25356042
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Islet G-protein coupled receptors: therapeutic potential for diabetes.
    Persaud SJ
    Curr Opin Pharmacol; 2017 Dec; 37():24-28. PubMed ID: 28822846
    [TBL] [Abstract][Full Text] [Related]  

  • 60. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.